RxDoctor Payments Data

Patrick Doran, PA

Medical · Battle Creek, MINPI 1295084267

Payments from drug & device makers

$781in general payments, 2019–2025

Across 32 payments — averaging $24.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$315
  • Novo Nordisk$186
  • Axsome Therapeutics, Inc.$83
  • Biohaven Pharmaceutical Holding Company Ltd.$70
  • Lilly USA, LLC$32
  • Biohaven Pharmaceuticals, Inc.$26
  • plus $70 from 3 others

What the payments were for

  • Food & beverage$781100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$781 in reported general payments places this provider in the 60th percentile of 755 medical providers in Michigan.

See all medical providers in Michigan

Medicare billing

Part B allowed, 2024
$59,193
Medicare patients
225
Services billed
1,668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter100$66,193
EliquisApixaban51$58,166
TrulicityDulaglutide48$53,934
XareltoRivaroxaban37$44,089
OzempicSemaglutide32$43,803
RybelsusSemaglutide15$18,670
JanuviaSitagliptin Phosphate21$18,310
JardianceEmpagliflozin14$17,142
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$11,934
ShingrixVaricella-Zoster Ge/As01b/Pf43$9,618
SymbicortBudesonide/Formoterol Fumarate17$8,645
ArexvyRsvpref3 Antigen/As01e/Pf22$6,769
Atorvastatin Calcium323$4,187
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen160$3,984
Omeprazole167$2,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$186$62,47447 claims
PfizerEliquis$315$58,16651 claims
Lilly USA, LLCTrulicity$32$53,93448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 755 medical providers in Michigan.

Other medical in Battle Creek

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →